Profusa Stock Spikes As Lumee System Targets Research Market

Profusa, Inc. (NASDAQ:PFSA) stock rallied on Friday as the company is launching its Healthcare Research version of the Lumee tissue oxygen monitoring system. The stock is trading with a massive volume of 140.93 million versus the average volume of 25.7 million, according to Benzinga Pro data. The company announced that its Lumee tissue oxygen products are now commercially available for contract research organizations (CROs), targeting a market projected to grow from approximately $47.9 billion in 2025 to over $91.2 billion by 2034 at a CAGR of more than 7%. This strategic move is expected to generate immediate service-based revenue and enhance drug development efficiency by providing real-time biological data. Profusa’s Lumee tissue oxygen system will be offered as research-use-only kits, allowing CRO partners to incorporate the technology into existing study designs with minimal implementation risk. This provides researchers and R&D teams access to continuous, real-time measurement of tissue oxygenation, providing critical insights across a range of applications, including advanced in vitro and organ-on-chip models, preclinical pharmacology and toxicology studies, and translational research programs. The company has appointed Sean Givens to lead commercialization efforts, emphasizing the strong interest in their validated sensors across the industry. Profusa Technical Analysis The stock is currently trading 21.2% above its 20-day simple moving average (SMA) but is 51.3% below its 100-day SMA, indicating a short-term bullish trend while struggling in the longer term. Shares have decreased 94.35% over the past 12 months and are currently positioned closer to their 52-week lows than highs. The RSI is at 44.33, which is considered neutral territory, suggesting that there is no immediate overbought or oversold condition. Meanwhile, MACD is above its signal line, indicating a bullish momentum that could support further price increases. The combination of neutral RSI and bullish MACD suggests mixed momentum, which may lead to cautious optimism among traders. Key Resistance: $0.14 Key Support: $0.09 PFSA Price Action: Profusa stock is up 20.30% at $0.12 at the time of publication on Friday, according to Benzinga Pro data. Photo: Gorodenkoff via Shutterstock